15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $403M | -$23M | 0.0% | 15.0% | -$13M | — | $168M |
| 2024 | $332M | -$52M | 0.0% | 16.4% | -$24M | — | $145M |
| 2023 | $116M | -$209M | 0.0% | -133.7% | -$135M | — | $82M |
| 2022 | $75M | -$234M | 0.0% | -237.8% | -$175M | — | $125M |
| 2021 | $78M | -$269M | 0.0% | -289.0% | -$264M | — | $209M |
| 2020 | $228M | -$144M | 0.0% | -53.3% | -$86M | — | $305M |
| 2019 | $148M | -$97M | 0.0% | -62.8% | -$71M | — | $166M |
| 2018 | $0 | -$202M | — | — | -$149M | — | $37M |
| 2017 | — | -$167M | — | — | -$131M | — | $34M |
| 2016 | — | -$75M | — | — | -$48M | $3M | $38M |
| 2015 | — | -$50M | — | — | -$38M | $4M | $77M |
| 2014 | — | -$36M | — | — | — | $5M | $85M |
| 2014 | — | -$76M | — | — | — | — | $49M |
| 2013 | — | -$26M | — | — | — | — | $57M |
| 2013 | — | -$58M | — | — | — | — | $72M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $80M | -$25M | 0.0% | -8.2% | -$28M | — | $156M |
| Dec '25 | $168M | $62M | 0.0% | 50.6% | $45M | — | $168M |
| Sep '25 | $87M | -$31M | 0.0% | -11.4% | -$4M | — | $92M |
| Jun '25 | $82M | -$13M | 0.0% | 8.6% | -$31M | — | $86M |
| Mar '25 | $65M | -$40M | 0.0% | -34.0% | -$23M | — | $115M |
| Dec '24 | $69M | -$21M | 0.0% | -6.4% | -$35M | — | $145M |
| Sep '24 | $52M | -$30M | 0.0% | -31.0% | -$35M | — | $145M |
| Jun '24 | $74M | -$62M | 0.0% | 3.5% | -$7M | — | $189M |
| Mar '24 | $138M | $61M | 0.0% | 52.5% | $54M | — | $227M |
| Dec '23 | $32M | -$56M | 0.0% | -131.4% | -$37M | — | $82M |
| Sep '23 | $34M | -$41M | 0.0% | -81.1% | -$19M | — | $115M |
| Jun '23 | $26M | -$50M | 0.0% | -143.7% | -$25M | — | $138M |
| Mar '23 | $24M | -$62M | 0.0% | -199.8% | -$54M | — | $145M |
| Dec '22 | $19M | -$55M | 0.0% | -225.9% | — | — | $125M |
| Sep '22 | $19M | -$55M | 0.0% | -219.3% | — | — | $159M |
| Jun '22 | $19M | -$66M | 0.0% | -278.0% | — | — | $123M |
| Mar '22 | $19M | -$57M | 0.0% | -228.2% | — | — | $150M |
| Dec '21 | $15M | -$65M | 0.0% | -361.2% | -$58M | — | $209M |
| Sep '21 | $14M | -$69M | 0.0% | -386.9% | -$69M | — | $104M |
| Jun '21 | $41M | -$44M | 0.0% | -80.0% | -$48M | — | $219M |
How the market has priced ESPR against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Esperion Therapeutics, Inc.'s revenue has grown 12.1% per year. These are computed facts, not advice.
As of FY2025, Esperion Therapeutics, Inc. reported — of total debt against $168M of cash; operating income covered interest expense 0.7×.
In FY2025, gross margin was —, operating margin 15.0%, and net margin -5.6%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.